Immune cell regulation by autocrine purinergic signalling

Nature Reviews Immunology

Volumn 11, Issue 3, 2011, Pages 201-212

  Junger, Wolfgang G ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; GAP JUNCTION PROTEIN; PURINERGIC P2X1 RECEPTOR; PURINERGIC P2X2 RECEPTOR; PURINERGIC P2X3 RECEPTOR; PURINERGIC P2X4 RECEPTOR; PURINERGIC P2X5 RECEPTOR; PURINERGIC P2X6 RECEPTOR; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y11 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y13 RECEPTOR; PURINERGIC P2Y2 RECEPTOR; PURINERGIC P2Y4 RECEPTOR; PURINERGIC RECEPTOR;

ADAPTIVE IMMUNITY; AUTOCRINE EFFECT; CELL ACTIVATION; HYDROLYSIS; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INNATE IMMUNITY; INTRACELLULAR SIGNALING; MACROPHAGE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADAPTIVE IMMUNITY; ADENOSINE; ADENOSINE TRIPHOSPHATE; ANIMALS; AUTOCRINE COMMUNICATION; CHEMOTAXIS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; LEUKOCYTES; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MACROPHAGES; NOD SIGNALING ADAPTOR PROTEINS; NUCLEOSIDE TRANSPORT PROTEINS; PYROPHOSPHATASES; RECEPTORS, PURINERGIC; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 79952192382     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2938     Document Type: Review

References (123)

1. Burnstock, G., Fredholm, B. B., North, R. A. & Verkhratsky, A. The birth and postnatal development of purinergic signalling. Acta Physiol. 199, 93-147 (2010).
2. Ralevic, V. & Burnstock, G. Receptors for purines and pyrimidines. Pharmacol. Rev. 50, 413-492 (1998). (Pubitemid 28477681)
3. Zimmermann, H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch. Pharmacol. 362, 299-309 (2000).
4. Burnstock, G. Unresolved issues and controversies in purinergic signalling. J. Physiol. 586, 3307-3312 (2008). (Pubitemid 352005793)
5. Corriden, R. & Insel, P. A. Basal release of ATP: an autocrine-paracrine mechanism for cell regulation. Sci. Signal. 3, re1 (2010).
6. Abbracchio, M. P., Burnstock, G., Verkhratsky, A. & Zimmermann, H. Purinergic signalling in the nervous system: an overview. Trends Neurosci. 32, 19-29 (2009).
7. Bours, M. J., Swennen, E. L., Di Virgilio, F., Cronstein, B. N. & Dagnelie, P. C. Adenosine 5-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol. Ther. 112, 358-404 (2006). (Pubitemid 44486409)
8. Filippini, A., Taffs, R. E. & Sitkovsky, M. V. Extracellular ATP in T lymphocyte activation: possible role in effector functions. Proc. Natl Acad. Sci. USA 87, 8267-8271 (1990).
9. Schenk, U. et al. Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci. Signal. 1, ra6 (2008).
10. Yip, L. et al. Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J. 23, 1685-1693 (2009).
11. Woehrle, T. et al. Pannexin-1 hemichannel-mediated ATP release together with P2X1 and P2X4 receptors regulate T cell activation at the immune synapse. Blood 116, 3475-3484 (2010).
12. Chen, Y. et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 314, 1792-1795 (2006). (Pubitemid 44969094)
13. Elliott, M. R. et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461, 282-286 (2009).
14. Trautmann, A. Extracellular ATP in the immune system: more than just a "danger signal". Sci. Signal. 2, pe6 (2009).
15. Praetorius, H. A. & Leipziger, J. ATP release from non-excitable cells. Purinergic Signal. 5, 433-446 (2009). Abbracchio. et al. International Union of Pharmacology LVIII: update on the P2Y G proteincoupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol. Rev. 58, 281-341 (2006).
16. Burnstock, G. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol. Rev. 58, 58-86 (2006).
17. Yegutkin, G. G. Nucleotide-and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim. Biophys. Acta 1783, 673-694 (2008).
18. Di Virgilio, F. Purinergic mechanism in the immune system: a signal of danger for dendritic cells. Purinergic Signal. 1, 205-209 (2005). (Pubitemid 41136025)
19. Ravichandran, K. S. Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums. J. Exp. Med. 207, 1807-1817 (2010).
20. Schroder, K. & Tschopp, J. The inflammasomes. Cell 140, 821-832 (2010).
21. Burnstock, G. Purinergic signalling and disorders of the central nervous system. Nature Rev. Drug Discov. 7, 575-590 (2008). (Pubitemid 351927723)
22. Dahl, G. & Locovei, S. Pannexin: to gap or not to gap, is that a question? IUBMB Life 58, 409-419 (2006). (Pubitemid 43995626)
23. Laird, D. W. Life cycle of connexins in health and disease. Biochem. J. 394, 527-543 (2006).
24. MacVicar, B. A. & Thompson, R. J. Non-junction functions of pannexin-1 channels. Trends Neurosci. 33, 93-102 (2010).
25. Eltzschig, H. K. et al. ATP release from activated neutrophils occurs via connexin 43 and modulates adenosine-dependent endothelial cell function. Circ. Res. 99, 1100-1108 (2006). (Pubitemid 44729934)
26. Chen, Y. et al. Purinergic signaling: a fundamental mechanism in neutrophil activation. Sci. Signal. 3, ra45 (2010).
27. Beldi, G. et al. The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism. Front. Biosci. 13, 2588-2603 (2008).
28. Gray, J. H., Owen, R. P. & Giacomini, K. M. The concentrative nucleoside transporter family, SLC28. Pflugers Arch. 447, 728-734 (2004). (Pubitemid 38241458)
29. Baldwin, S. A. et al. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch. 447, 735-743 (2004). (Pubitemid 38241459)
30. Franco, R., Valenzuela, A., Lluis, C. & Blanco, J. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. Immunol. Rev. 161, 27-42 (1998).
31. Cristalli, G. et al. Adenosine deaminase: functional implications and different classes of inhibitors. Med. Res. Rev. 21, 105-128 (2001). (Pubitemid 32185243)
32. Kameoka, J., Tanaka, T., Nojima, Y., Schlossman, S. F. & Morimoto, C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 261, 466-469 (1993). (Pubitemid 23276554)
33. Ciruela, F. et al. Adenosine deaminase affects ligandinduced signalling by interacting with cell surface adenosine receptors. FEBS Lett. 380, 219-223 (1996). (Pubitemid 26063938)
34. Herrera, C. et al. Adenosine A2B receptors behave as an alternative anchoring protein for cell surface adenosine deaminase in lymphocytes and cultured cells. Mol. Pharmacol. 59, 127-134 (2001). (Pubitemid 32043094)
35. Franco, R., Pacheco, R., Gatell, J. M., Gallart, T. & Lluis, C. Enzymatic and extraenzymatic role of adenosine deaminase 1 in T-cell-dendritic cell contacts and in alterations of the immune function. Crit. Rev. Immunol. 27, 495-509 (2007).
36. Zavialov, A. V. et al. Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J. Leukoc. Biol. 88, 279-290 (2010).
37. Apasov, S. G. & Sitkovsky, M. V. The extracellular versus intracellular mechanisms of inhibition of TCRtriggered activation in thymocytes by adenosine under conditions of inhibited adenosine deaminase. Int. Immunol. 11, 179-189 (1999). (Pubitemid 29074092)
38. Apasov, S. G., Blackburn, M. R., Kellems, R. E., Smith, P. T. & Sitkovsky, M. V. Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling. J. Clin. Invest. 108, 131-141 (2001). (Pubitemid 32634930)
39. Molina-Arcas, M., Casado, F. J. & Pastor-Anglada, M. Nucleoside transporter proteins. Curr. Vasc. Pharmacol. 7, 426-434 (2009).
40. King, A. E., Ackley, M. A., Cass, C. E., Young, J. D. & Baldwin, S. A. Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol. Sci. 27, 416-425 (2006). (Pubitemid 44051567)
41. Kichenin, K., Pignede, G., Fudalej, F. & Seman, M. CD3 activation induces concentrative nucleoside transport in human T lymphocytes. Eur. J. Immunol. 30, 366-370 (2000). (Pubitemid 30098828)
42. Soler, C. et al. Regulation of nucleoside transport by lipopolysaccharide, phorbol esters, and tumor necrosis factor-α in human B-lymphocytes. J. Biol. Chem. 273, 26939-26945 (1998). (Pubitemid 28471715)
43. Soler, C. et al. Macrophages require different nucleoside transport systems for proliferation and activation. FASEB J. 15, 1979-1988 (2001). (Pubitemid 32848802)
44. Smith, C. L., Pilarski, L. M., Egerton, M. L. & Wiley, J. S. Nucleoside transport and proliferative rate in human thymocytes and lymphocytes. Blood 74, 2038-2042 (1989). (Pubitemid 19269107)
45. Jarvis, M. F. & Khakh, B. S. ATP-gated P2X cationchannels. Neuropharmacology 56, 208-215 (2009).
46. Janetopoulos, C. & Firtel, R. A. Directional sensing during chemotaxis. FEBS Lett. 582, 2075-2085 (2008).
47. Choudhuri, K. & van der Merwe, P. A. Molecular mechanisms involved in T cell receptor triggering. Semin. Immunol. 19, 255-261 (2007). (Pubitemid 47043486)
48. Corriden, R. et al. Ecto-nucleoside triphosphate diphosphohydrolase 1 (E-NTPDase1/CD39) regulates neutrophil chemotaxis by hydrolyzing released ATP to adenosine. J. Biol. Chem. 283, 28480-28486 (2008).
49. Junger, W. G. Purinergic regulation of neutrophil chemotaxis. Cell. Mol. Life Sci. 65, 2528-2540 (2008).
50. Cronstein, B. N. Adenosine, an endogenous antiinflammatory agent. J. Appl. Physiol. 76, 5-13 (1994).
51. Fredholm, B. B. Purines and neutrophil leukocytes. Gen. Pharmacol. 28, 345-350 (1997). (Pubitemid 27116194)
52. Ward, P. A., Cunningham, T. W., McCulloch, K. K. & Johnson, K. J. Regulatory effects of adenosine and adenine nucleotides on oxygen radical responses of neutrophils. Lab. Invest. 58, 438-447 (1988).
53. Zhang, Y., Palmblad, J. & Fredholm, B. B. Biphasic effect of ATP on neutrophil functions mediated by P2U and adenosine A2A receptors. Biochem. Pharmacol. 51, 957-965 (1996).
54. de la Harpe, J. & Nathan, C. F. Adenosine regulates the respiratory burst of cytokine-triggered human neutrophils adherent to biologic surfaces. J. Immunol. 143, 596-602 (1989). (Pubitemid 19191557)
55. Meshki, J., Tuluc, F., Bredetean, O., Ding, Z. & Kunapuli, S. P. Molecular mechanism of nucleotideinduced primary granule release in human neutrophils: role for the P2Y2 receptor. Am. J. Physiol. Cell Physiol. 286, C264-C271 (2004). (Pubitemid 38146350)
56. Verghese, M. W., Kneisler, T. B. & Boucheron, J. A. P2U agonists induce chemotaxis and actin polymerization in human neutrophils and differentiated HL60 cells. J. Biol. Chem. 271, 15597-15601 (1996). (Pubitemid 26225333)
57. Kronlage, M. et al. Autocrine purinergic receptor signaling is essential for macrophage chemotaxis. Sci. Signal. 3, ra55 (2010).
58. Orr, A. G., Orr, A. L., Li, X. J., Gross, R. E. & Traynelis, S. F. Adenosine A2A receptor mediates microglial process retraction. Nature Neurosci. 12, 872-878 (2009).
59. Kukulski, F. et al. Extracellular ATP and P2 receptors are required for IL-8 to induce neutrophil migration. Cytokine 46, 166-170 (2009).
60. Lecut, C. et al. P2X1 ion channels promote neutrophil chemotaxis through Rho kinase activation. J. Immunol. 183, 2801-2909 (2009).
61. Honda, S. et al. Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors. J. Neurosci. 21, 1975-1982 (2001). (Pubitemid 32221381)
62. Inoue, K. Purinergic systems in microglia. Cell. Mol. Life Sci. 65, 3074-3080 (2008).
63. Davalos, D. et al. ATP mediates rapid microglial response to local brain injury in vivo. Nature Neurosci. 8, 752-758 (2005). (Pubitemid 43085841)
64. Nimmerjahn, A., Kirchhoff, F. & Helmchen, F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314-1318 (2005). (Pubitemid 40746128)
65. Haynes, S. E. et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nature Neurosci. 9, 1512-1519 (2006). (Pubitemid 44862659)
66. Koizumi, S. et al. UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature 446, 1091-1095 (2007). (Pubitemid 46676051)
67. McCloskey, M. A., Fan, Y. & Luther, S. Chemotaxis of rat mast cells toward adenine nucleotides. J. Immunol. 163, 970-977 (1999). (Pubitemid 29328109)
68. Liu, Q. H. et al. Expression and a role of functionally coupled P2Y receptors in human dendritic cells. FEBS Lett. 445, 402-408 (1999). (Pubitemid 29117252)
69. Schnurr, M. et al. ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling. Blood 102, 613-620 (2003). (Pubitemid 36841983)
70. Müller, T. et al. The purinergic receptor P2Y2 receptor mediates chemotaxis of dendritic cells and eosinophils in allergic lung inflammation. Allergy 65, 1545-1553 (2010).
71. Piccini, A. et al. ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1β and IL-18 secretion in an autocrine way. Proc. Natl Acad. Sci. USA 105, 8067-8072 (2008). (Pubitemid 351904709)
72. Kukulski, F. et al. Endothelial P2Y2 receptor regulates LPS-induced neutrophil transendothelial migration in vitro. Mol. Immunol. 47, 991-999 (2010).
73. Ben Yebdri, F., Kukulski, F., Tremblay, A. & Sévigny, J. Concomitant activation of P2Y2 and P2Y6 receptors on monocytes is required for TLR1/2-induced neutrophil migration by regulating IL-8 secretion. Eur. J. Immunol. 39, 2885-2894 (2009).
74. Hyman, M. C. et al. Self-regulation of inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39. J. Clin. Invest. 119, 1136-1149 (2009).
75. McDonald, B. et al. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 330, 362-366 (2010).
76. Chekeni, F. B. et al. Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature 467, 863-867 (2010).
77. Valitutti, S., Müller, S., Cella, M., Padovan, E. & Lanzavecchia, A. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375, 148-151 (1995).
78. van der Merwe, P. A. The TCR triggering puzzle. Immunity 14, 665-668 (2001).
79. Ma, Z. & Finkel, T. H. T cell receptor triggering by force. Trends Immunol. 31, 1-6 (2010).
80. Canaday, D. H. et al. ATP and control of intracellular growth of mycobacteria by T cells. Infect. Immun. 70, 6456-6459 (2002). (Pubitemid 35192740)
81. Into, T., Okada, K., Inoue, N., Yasuda, M. & Shibata, K. Extracellular ATP regulates cell death of lymphocytes and monocytes induced by membrane-bound lipoproteins of Mycoplasma fermentans and Mycoplasma salivarium. Microbiol. Immunol. 46, 667-675 (2002). (Pubitemid 35238846)
82. Di Virgilio, F. et al. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 97, 587-600 (2001). (Pubitemid 32113390)
83. Wang, L., Jacobsen, S. E., Bengtsson, A. & Erlinge, D. P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells. BMC Immunol. 5, 16 (2004).
84. Leal, D. B. et al. Characterization of NTPDase (NTPDase1; ectoapyrase; ecto-diphosphohydrolase; CD39; EC3. 6.1.5) activity in human lymphocytes. Biochim. Biophys. Acta 1721, 9-15 (2005). (Pubitemid 40093507)
85. Lee, D. H., Park, K. S., Kong, I. D., Kim, J. W. & Han, B. G. Expression of P2 receptors in human B cells and Epstein-Barr virus-transformed lymphoblastoid cell lines. BMC Immunol. 7, 22 (2006).
86. Beldi, G. et al. Deletion of CD39 on natural killer cells attenuates hepatic ischemia/reperfusion injury in mice. Hepatology 51, 1702-1711 (2010).
87. Padeh, S., Cohen, A. & Roifman, C. M. ATP-induced activation of human B lymphocytes via P2-purinoceptors. J. Immunol. 146, 1626-1632 (1991).
88. Sakowicz-Burkiewicz, M., Kocbuch, K., Grden, M., Szutowicz, A. & Pawelczyk, T. Adenosine 5-triphosphate is the predominant source of peripheral adenosine in human B lymphoblasts. J. Physiol. Pharmacol. 61, 491-499 (2010).
89. Gorini, S. et al. ATP secreted by endothelial cells blocks CX3CL1-elicited natural killer cell chemotaxis and cytotoxicity via P2Y11 receptor activation. Blood 116, 4492-4500 (2010).
90. Sumi, Y. et al. Adrenergic receptor activation involves ATP release and feedback through purinergic receptors. Am. J. Physiol. Cell Physiol. 299, C1118-C1126 (2010).
91. Peter, C., Wesselborg, S. & Lauber, K. Molecular suicide notes: last call from apoptosing cells. J. Mol. Cell. Biol. 2, 78-80 (2010).
92. Zhang, Q. et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464, 104-107 (2010).
93. Franchi, L., Warner, N., Viani, K. & Nuñez, G. Function of Nod-like receptors in microbial recognition and host defense. Immunol. Rev. 227, 106-128 (2009).
94. Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nature Med. 15, 1170-1178 (2009).
95. Boeynaems, J. M. & Communi, D. Modulation of inflammation by extracellular nucleotides. J. Invest. Dermatol. 126, 943-944 (2006).
96. Di Virgilio, F., Boeynaems, J. M. & Robson, S. C. Extracellular nucleotides as negative modulators of immunity. Curr. Opin. Pharmacol. 9, 507-713 (2009).
97. Kaufmann, A. et al. "Host tissue damage" signal ATP promotes non-directional migration and negatively regulates Toll-like receptor signaling in human monocytes. J. Biol. Chem. 280, 32459-32467 (2005). (Pubitemid 41361858)
98. Duhant, X. et al. Extracellular adenine nucleotides inhibit the activation of human CD4+ T lymphocytes. J. Immunol. 169, 15-21 (2002). (Pubitemid 34686114)
99. Chen, Y., Shukla, A., Namiki, S., Insel, P. A. & Junger, W. G. A putative osmoreceptor system that controls neutrophil function through the release of ATP, its conversion to adenosine, and activation of A2 adenosine and P2 receptors. J. Leukoc. Biol. 76, 245-253 (2004). (Pubitemid 38857193)
100. Chen, Y., Hashiguchi, N., Yip, L. & Junger, W. G. Hypertonic saline enhances neutrophil elastase release through activation of P2 and A3 receptors. Am. J. Physiol. Cell Physiol. 290, C1051-C1059 (2006).
101. Yip, L. et al. Hypertonic stress regulates T-cell function by the opposing actions of extracellular adenosine triphosphate and adenosine. Shock 27, 242-250 (2007).
102. Mizumoto, N. et al. CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nature Med. 8, 358-365 (2002). (Pubitemid 34407030)
103. Stagg, J. & Smyth, M. J. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29, 5346-5358 (2010).
104. Otha, A. et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl Acad. Sci. USA 103, 13132-13137 (2006).
105. Ohtsuka, T. et al. Ecto-5-nucleotidase (CD73) attenuates allograft airway rejection through adenosine 2A receptor stimulation. J. Immunol. 185, 1321-1329 (2010).
106. Sevigny, C. P. et al. Activation of adenosine 2A receptors attenuates allograft rejection and alloantigen recognition. J. Immunol. 178, 4240-4249 (2007). (Pubitemid 46492374)
107. Deaglio, S. et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257-1265 (2007). (Pubitemid 46919862)
108. Sun, X. et al. CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology 139,1030-1040 (2010).
109. Inoue, Y., Chen, Y., Hirsh, M. I., Yip, L. & Junger, W. G. A3 and P2Y2 receptors control the recruitment of neutrophils to the lungs in a mouse model of sepsis. Shock 30, 173-177 (2008).
110. Fredholm, B. B. Adenosine receptors as drug targets. Exp. Cell Res. 316, 1284-1288 (2010).
111. Price, M. J. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 119, 2625-2632 (2009).
112. Kam, P. C. & Nethery, C. M. The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia 58, 28-35 (2003). (Pubitemid 36113325)
113. Jacobson, K. A. & Gao, Z. G. Adenosine receptors as therapeutic targets. Nature Rev. Drug Discov. 5, 247-264 (2006). (Pubitemid 43336037)
114. Baraldi, P. G., Tabrizi, M. A., Gessi, S. & Borea, P. A. Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility. Chem. Rev. 108, 238-263 (2008). (Pubitemid 351176408)
115. Haskó, G., Linden, J., Cronstein, B. & Pacher, P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nature Rev. Drug Discov. 7, 759-770 (2008).
116. Cronstein, B. N. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol. Rev. 57, 163-172 (2005). (Pubitemid 41043882)
117. Cronstein, B. N., Naime, D. & Ostad, E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest. 92, 2675-2682 (1993). (Pubitemid 24006532)
118. Baharav, E. et al. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J. Rheumatol. 32, 469-476 (2005). (Pubitemid 40381417)
119. Bar-Yehuda, S. et al. The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opin. Investig. Drugs 16, 1601-1613 (2007). (Pubitemid 350028410)
120. Silverman, M. H. et al. Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J. Rheumatol. 35, 41-48 (2008).
121. Corriden, R., Insel, P. A. & Junger, W. G. A novel method using fluorescence microscopy for real-time assessment of ATP release from individual cells. Am. J. Physiol. Cell Physiol. 293, C1420-C1425 (2007). (Pubitemid 47556749)
122. Pellegatti, P., Falzoni, S., Pinton, P., Rizzuto, R. & Di Virgilio, F. A novel recombinant plasma membrane-targeted luciferase reveals a new pathway for ATP secretion. Mol. Biol. Cell 16, 3659-3665 (2005). (Pubitemid 41077076)
123. Pellegatti, P. et al. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS ONE 3, e2599 (2008).